ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Romosozumab in severe postmenopausal osteoporosis-real-world data from 192 women.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Romosozumab, used to treat severe osteoporosis, still lacks real-world treatment data. We observed significant gains in spinal and hip bone mineral density, as well as improvements in trabecular microarchitecture. These real-world observations corroborate controlled trials and provide new insights into sequential therapy effects and the management of severe osteoporosis. PURPOSE: Osteoporosis is a common disease that leads to fractures causing immobility and pain. Pharmacological therapy plays a pivotal role in osteoporosis management with a growing number of approved drugs. Romosozumab, an anti-sclerostin antibody, is approved in several countries for the treatment of severe osteoporosis in postmenopausal women. Clinical trials have demonstrated significant gain of areal bone mineral density (aBMD) in these patients over 12 months of treatment; however, real-world data is still limited.
methodsFrom 2020 to 2024, 192 postmenopausal women with severe osteoporosis treated with romosozumab were identified at our institution. Clinical data from a 24-month observation period were analyzed, comprising aBMD by dual-energy X-ray absorptiometry (DXA), bone microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), and biochemical bone turnover markers.
resultsPatients treated with romosozumab showed significant gains in spinal (L1-L4) and hip aBMD (lumbar spine: 14.47 ± 8.74%, p < 0.001; total hip: 4.15 ± 5.92%, p < 0.001), accompanied by an increase in bone formation parameters after 6 months and an increase in trabecular microarchitectural parameters assessed by HR-pQCT in 12-month follow-up. These changes were significantly lower in patients with previous bone specific treatment. Treatment-naïve (TN) patients benefited significantly more than those previously treated with antiresorptive (AR) medication (lumbar spine aBMD change: TN: 17.74 ± 8.30%, AR: 10.44 ± 7.67%, p < 0.001). This was supported by the dependency of aBMD gain on baseline bone formation markers.
conclusionOur real-world data corroborate the results from controlled studies and provide new insights into microstructural changes as well as biochemical treatment monitoring. To fully evaluate sequential therapy, larger studies and longer observation times are needed in the future.
Indexed as
Identifiers
42417976What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.